Kling Bio and Sanofi Unite to Advance Next-Gen Antiviral Therapies
Kling Bio has announced a major step forward in the field of antibody discovery, unveiling a new collaboration and licence option agreement with global healthcare leader Sanofi.
The alliance will utilise Kling Bio’s proprietary B cell platform, Kling-Select, in a focused effort to accelerate the discovery of neutralising monoclonal antibodies against a clinically relevant human viral pathogen.
This strategic partnership is poised to fuel the development of next-generation antiviral therapies, while also providing valuable insights that may influence future vaccine design. It reflects a shared vision between the two companies: to address urgent global health challenges through cutting-edge science and innovation.
A Platform with Proven Power
At the heart of the collaboration lies Kling-Select – Kling Bio’s clinically and commercially validated B cell immortalisation and screening platform.
Unlike traditional systems, Kling-Select uses patient-derived B cells to rapidly identify rare, immuno-functional antibodies and conserved viral epitopes.
Its function-first screening workflow has been instrumental in discovering validated candidates against viruses such as RSV, COVID-19, and influenza, marking it as a powerful and adaptable tool for vaccine and therapeutic development.
By enabling scientists to explore a direct window into the human immune response, Kling-Select accelerates the identification of functional antibodies with therapeutic potential – providing a faster, more accurate route to breakthrough treatments.
Leadership Comments on the Partnership
Speaking about the agreement, Kling Bio’s Chief Executive Officer shared a clear sense of purpose and momentum.
They expressed that this collaboration with Sanofi highlights the broad potential of their Kling-Select platform to address global health challenges by enabling the discovery of first-in-class, human-derived antibodies.
Furthermore, Kling-Select provides a powerful window into the human immune response and accelerates the identification of functional antibodies and novel epitopes.
The CEO also emphasised the synergy between the two companies, noting Kling Bio’s excitement in combining its discovery expertise with Sanofi’s leadership in vaccine development.
A Commitment to Scientific Progress
With this partnership, both Kling Bio and Sanofi are doubling down on their commitment to transforming the landscape of disease prevention and treatment.
The collaboration is more than a business arrangement – it’s a reflection of shared goals: using advanced antibody discovery technologies to solve some of the most pressing public health challenges of the present time.
Conclusion
As the global community continues to confront a changing viral threat landscape, partnerships like this one between Kling Bio and Sanofi are critical.
By leveraging the cutting-edge capabilities of Kling-Select and Sanofi’s vast vaccine development infrastructure, this collaboration sets the stage for the next wave of antiviral therapeutics and vaccine innovation.
It is a bold and timely step toward a healthier, more prepared future.
News Credits: Kling Bio partners with Sanofi to accelerate antibody discovery
Things you may also like: